Helix BioPharma (TSE:HBP) Stock Price Passes Below 200-Day Moving Average – Should You Sell?

Helix BioPharma Corp. (TSE:HBP)’s share price passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of C$2.05 and traded as low as C$1.58. Helix BioPharma shares last traded at C$1.58, with a volume of 128 shares changing hands.

Helix BioPharma Stock Up 0.6%

The company has a quick ratio of 1.04, a current ratio of 0.04 and a debt-to-equity ratio of 2.34. The company has a market cap of C$120.68 million, a P/E ratio of -26.33 and a beta of 0.40. The company has a fifty day moving average of C$1.84 and a 200 day moving average of C$2.05.

Helix BioPharma (TSE:HBP) last issued its quarterly earnings data on Monday, March 16th. The biopharmaceutical company reported C($0.01) EPS for the quarter. On average, research analysts anticipate that Helix BioPharma Corp. will post -0.11 earnings per share for the current fiscal year.

Helix BioPharma Company Profile

Helix BioPharma is an oncology company that innovates from strength to bring near-term solutions for today’s hardest-to-treat cancers. The Company’s pipeline is led by Tumor Defense Breaker¿ L-DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy and augment the effectiveness of today’s front-running anti-cancer treatments. L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC) and shares its CEACAM6-targeting foundation with Helix’s next-generation bi-specific antibody-drug conjugates (ADCs), currently in discovery.